17797-11-4

Basic information

• Product Name: 1-(4-CHLOROPHENYL)-1-METHYLETHYLAMINE
• Synonyms: 1-(4-CHLOROPHENYL)-1-METHYLETHYLAMINE;1-(4-Chlorophenyl)-1-methyleth;2-(4-Chlorophenyl)propan-2-amine;BenzeneMethanaMine, 4-chloro-a,a-diMethyl-;1-(4-Chlorophenyl)-1-methylethylamine, 4-Chloro-alpha,alpha-dimethylbenzylamine, alpha-Amino-4-chlorocumene;2-(4-Chlorophenyl)propan-2-amine, HCl
• CAS NO: 17797-11-4
• Molecular Formula: C₉H₁₂ClN
• Molecular Weight: 169.65128
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 17797-11-4.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 43-45℃/0.3mm
• Flash Point: 110.926 °C
• Appearance: /
• Density: 1.093 g/cm³
• Vapor Pressure: 0.045mmHg at 25°C
• Refractive Index: 1.5330
• Storage Temp.: 2-8°C
• PKA: 9.15±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 1-(4-CHLOROPHENYL)-1-METHYLETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROPHENYL)-1-METHYLETHYLAMINE(17797-11-4)
• EPA Substance Registry System: 1-(4-CHLOROPHENYL)-1-METHYLETHYLAMINE(17797-11-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: 8
• Hazardous Substances Data: 17797-11-4(Hazardous Substances Data)

Usage

General Description

1-(4-Chlorophenyl)-1-methylethylamine, also known as para-Chloroamphetamine (PCA), is a substituted phenethylamine compound with a chloro substitution at the para position of the phenyl ring. This chemical is a psychoactive and stimulant drug that belongs to the amphetamine class. It is known for its ability to increase levels of certain neurotransmitters in the brain, such as dopamine, norepinephrine, and serotonin, leading to effects such as euphoria, increased alertness, and enhanced mood. The compound has been studied for its potential therapeutic applications, but also has a history of abuse as a recreational drug due to its stimulant properties. Its use has been associated with potential adverse effects and health risks, including neurotoxicity and potential for addiction.

InChI:InChI=1/C9H12ClN/c1-9(2,11)7-3-5-8(10)6-4-7/h3-6H,11H2,1-2H3

Upstream product

• 623-03-0 4-Cyanochlorobenzene 
• 917-54-4 methyllithium 
• 6258-30-6 2-(4-chlorophenyl)-2-methylpropanoic acid 
• 30568-32-2 2-(4-chlorophenyl)-2-methylpropanenitrile 
• 1000141-65-0 1-(2-azidopropan-2-yl)-4-chlorobenzene 
• 99-91-2 para-chloroacetophenone 
• 1989-25-9 4-chlorocumyl alcohol 
• 94616-84-9 dichloromethylcerium 
• 619-56-7 4-chlorobenzamide 
• 2521-24-6 4-chlorothiobenzamide 
• 64798-38-5 1-chloro-4-(1-isocyanato-1-methylethyl)benzene 
• 2621-46-7 1-chloro-4-isopropylbenzene 

Downstream Products

• 1000141-68-3 C₁₈H₂₂Cl₂N₂O₂S 
• 66897-74-3 N-allyl-N-(α,α-dimethyl-4-chlorobenzyl)benzenesulfonamide 
• 1357456-29-1 C₂₉H₃₄Cl₂N₄OS 
• 1217337-03-5 5-(3-(2-(4-chlorophenyl)propan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 1202700-40-0 N-{[1-[(2-chlorophenyl)methyl]-5-({[1-(4-chlorophenyl)-1-methylethyl]amino}carbonyl)-4,6-dihydroxy-2-oxo-1,2-dihydro-3-pyridinyl]carbonyl}glycine 
• 1227936-69-7 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide 
• 1227946-70-4 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-6-carboxamide 
• 1227945-01-8 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-[1-(4-chlorophenyl)-1-methylethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrido[4,3-d]pyrimidine-7-carboxamide 
• 1217347-87-9 4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-chlorophenyl)-N-(2-(4-chlorophenyl)propan-2-yl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide 
• 21317-34-0 2,2'-Di-(p-chlor-phenyl)-<2,2'>azopropan 

Relevant articles and documents

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent

The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019–0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40–>120 μM) towards Vero cells. Significant improvements in mouse liver microsomal stability and mouse pharmacokinetic profile were realized by introduction of an α α-dimethylbenzyl moiety. Among these compounds, JSF-4088 is highlighted due to its in vitro antitubercular potency (MIC = 0.019 μM) and Vero cell cytotoxicity (CC50 > 120 μM). The findings suggest a rationale for the continued evolution of this promising series of antitubercular small molecules.

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.